Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health. 2008;2(1):24.

Article  PubMed  PubMed Central  Google Scholar 

Savla R, Browne J, Plassat V, Wasan KM, Wasan EK. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev Ind Pharm. 2017;43(11):1743–58.

Article  CAS  PubMed  Google Scholar 

Depacon (valproate sodium) for intravenous injection Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020593s026lbl.pdf. Accessed 10 Feb 2024.

Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 2007;73(3):275–83.

Article  CAS  PubMed  Google Scholar 

Dutta S, Faught E, Limdi NA. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Ther. 2007;32(4):365–71.

Article  CAS  PubMed  Google Scholar 

Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239–76.

Article  CAS  PubMed  Google Scholar 

Rahman M, Awosika AO, Nguyen H. Valproic acid. [Updated 2024 Mar 19]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from https://www.ncbi.nlm.nih.gov/books/NBK559112/. Accessed 24 June 2024.

Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther. 2006;13(3):211–7.

Article  PubMed  Google Scholar 

Weaving G, Batstone GF, Jones RG. Age and sex variation in serum albumin concentration: an observational study. Ann Clin Biochem. 2016;53(Pt 1):106–11.

Article  CAS  PubMed  Google Scholar 

Mclntyre N, Rosalki S. Tests of the functions of the liver. In: Williams DL, Marks V, editors. Scientific foundations of biochemistry in clinical practice, 2nd ed. 1994. p. 383–98.https://doi.org/10.1016/B978-0-7506-0167-2.50027-3

Conner TM, Nikolian VC, Georgoff PE, et al. Physiologically based pharmacokinetic modeling of disposition and drug–drug interactions for valproic acid and divalproex. Eur J Pharm Sci. 2018;111:465–81.

Article  CAS  PubMed  Google Scholar 

Depakene (valproic acid) Package insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/018081s071,018082s054lbl.pdf. Accessed 10 Feb 2024.

Wallenburg E, Klok B, de Jong K, et al. Monitoring protein-unbound valproic acid serum concentrations in clinical practice. Ther Drug Monit. 2017;39(3):269–72.

Article  CAS  PubMed  Google Scholar 

Burkat PM. Physiologically based pharmacokinetic and pharmacodynamic modeling of diazepam: unbound interstitial brain concentrations correspond to clinical end points. J Clin Pharmacol. 2022;62(10):1297–309.

Article  CAS  PubMed  Google Scholar 

Thiel C, Cordes H, Fabbri L, et al. A comparative analysis of drug-induced hepatotoxicity in clinically relevant situations. PLoS Comput Biol. 2017;13(2): e1005280.

Article  PubMed  PubMed Central  Google Scholar 

Ogungbenro K, Aarons L, CRESim & Epi-CRESim Project Groups. A physiologically based pharmacokinetic model for valproic acid in adults and children. Eur J Pharm Sci. 2014;63:45–52.

Article  CAS  PubMed  Google Scholar 

Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases [published correction appears in J Pharm Sci. 2007 Nov;96(11):3151-2]. J Pharm Sci. 2005;94(6):1259–76.

Article  CAS  PubMed  Google Scholar 

Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15(2):455–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit. 1989;11(2):127–33.

Article  CAS  PubMed  Google Scholar 

Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther. 1990;48(3):225–35.

Article  CAS  PubMed  Google Scholar 

Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Open Systems Pharmacology Suite Manual Version 7.0 Publication. Open Systems Pharmacology Suite Community License. 2017.

Parkinson H, Sarkans U, Kolesnikov N, et al. ArrayExpress update—an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 2011;39(Database issue):D1002–D1004.

Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589–96.

Article  CAS  PubMed  Google Scholar 

Llewelyn VK, Mangan MF, Glass BD. Stability of sodium valproate tablets repackaged into dose administration aids. J Pharm Pharmacol. 2010;62(7):838–43.

Article  CAS  PubMed  Google Scholar 

Yang S, Wang X, Jia J, Li P. Release property study on the novel divalproex sodium enteric-coated capsules. Saudi Pharm J. 2016;24(3):245–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akhtar J, Rana P, Jhanwar B. Formulation and evaluation of divalproex sodium enteric coated tablets. J Sci. 2011;1:21.

Google Scholar 

Qiu Y, Bollinger JD, et al, inventors; Abbott Laboratories, assignee. Controlled release formulation of divalproex sodium. US 6,720,004 B2. April 13, 2004.

Denney W, Duvvuri S, Buckeridge C. Simple, automatic noncompartmental analysis: the PKNCA R package. J Pharmacokinet Pharmacodyn. 2015;42(11–107):S65.

Google Scholar 

Horowitz IN, Tai K. Hypoalbuminemia in critically ill children. Arch Pediatr Adolesc Med. 2007;161(11):1048–52.

Article  PubMed  Google Scholar 

Gómez Bellver MJ, García Sánchez MJ, Alonso González AC, Santos Buelga D, Domínguez-Gil A. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther. 1993;18(3):191–7.

Article  PubMed  Google Scholar 

Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The ontogeny of UDP-glucuronosyltransferase enzymes, recommendations for future profiling studies and application through physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2019;58(2):189–211.

Article  PubMed  Google Scholar 

Krekels EHJ, Rower JE, Constance JE, Knibbe CAJ, Sherwin CMT. Hepatic drug metabolism in pediatric patients. In: Drug metabolism in diseases. Amsterdam: Elsevier Inc.; 2017. p. 181–206.

Chapter  Google Scholar 

Wanders RJ, Ruiter JP, Ijlst L, Waterham HR, Houten SM. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis. 2010;33(5):479–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatr Res. 2016;79(3):409–15.

Article  CAS  PubMed  Google Scholar 

Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int J Pharm. 1985;23:25–33.

Article